The presence of BCR-ABL1 transcript in ALL is associated with a relatively poor prognosis, necessitating the addition of tyrosine kinase inhibitor (TKI) into the treatment regimen [7]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.